Citigroup has downgraded Celgene (NASDAQ:CELG) from Buy to Neutral in a statement released on Friday October 20, 2017.
Only yesterday Celgene (NASDAQ:CELG) traded -0.88% lower at $135.96. Celgene’s 50-day moving average is $141.30 and its 200-day moving average is $130.43. With the last stock price up 4.24% relative to the two hundred day average, compared with the S&P 500 which has increased 0.03% over the same time. 5,700,001 shares of Celgene exchanged hands, up from an avg. volume of 3,710,920
Recent Performance Chart
With a total market value of $0, Celgene has PE ratio of 42.11 with a 52 week low of $96.93 and a 52 week high of $147.17 .
Also covering Celgene's target, a total of 22 equity analysts have released a ratings update on CELG. The 12-month price target is $136.82 with ten brokerages rating the company a strong buy, ten analysts rating the company a buy, four brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
About Celgene (NASDAQ:CELG)
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
The post Citigroup downgraded Celgene (NASDAQ:CELG) from Buy to Neutral in a report released today. appeared first on Octafinance.